The Prognostic Role of Sarcopenia in Wilms Tumor: Does It Influence Surgical Outcomes and Survival?
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31828 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Antonio J Muñoz-Serrano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Hospital Universitario La Paz, Madrid, Spain. Hauptthemen laut MEDLINE: Wilms Tumor, Sarcopenia, Kidney Neoplasms, Nephrectomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
Sarcopenia (SP) is described as a prognostic factor in adult and pediatric cancer patients. However, there are no data regarding Wilms tumor (WT). We aimed to study the association between sarcopenia and oncological outcomes in WT.
Methods
A retrospective study of patients diagnosed with WT at our institution between 2010 and 2022 was performed. SP at diagnosis was assessed by measuring the psoas muscle area (PMA) at the L4–L5 level on computed tomography (CT)/magnetic resonance imaging (MRI), and was defined as z ‐score values ≤2. Demographics, complications, and outcomes were analyzed.
Results
Forty‐eight patients (50% male) were included, with a mean age of 44.91 ± 31.12 months. Twelve patients (25%) had SP at diagnosis versus 36 (75%) who did not. Forty‐one patients (85%) underwent total nephrectomy and seven (15%) nephron‐sparing surgery (NSS). No statistical differences were found in demographics, risk group, or treatment between the SP and non‐sarcopenic (NSP) groups. SP was associated with a higher rate of postsurgical complications (33% for the SP‐group vs. 5.6% for the NSP‐group; p = 0.023) and with a higher rate of relapse (33% vs. 14%, respectively; p = 0.09). With a median follow‐up of 57.75 (1.87–150.8) months, event‐free survival (EFS) was lower for the SP group (84.20 ± 17.45 vs. 135.40 ± 8.65 months, respectively; p = 0,08). One patient in the SP group died. The 5‐year overall survival (OS) was 89% for the SP group versus 100% for the NSP group.
Conclusions
Among our patients, SP can be considered a risk factor for complications in patients with WT and could be associated with poor outcomes, increasing the risk of relapse and decreasing EFS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Surgery, Hospital Universitario La Paz, Madrid, Spain.
- Department of Pediatric Radiology, Hospital Universitario La Paz, Madrid, Spain.
- Medical School, Universidad Autónoma de Madrid, Madrid, Spain.
- Department of Pediatric Hematology and Oncology, Hospital Universitario La Paz, Madrid, Spain.
ORCID-Profile: Antonio J Muñoz-Serrano, Saturnino Barrena Delfa, Antonio Pérez-Martínez
Zitieren
APA
Muñoz-Serrano, A. J., Ramírez-Amoros, C., Barrena Delfa, S., Oterino, C., Navarro, G., Rubio Aparicio, P., Pérez-Martínez, A., Martínez-Urrutia, M. J., & Martínez, L. (2025). The Prognostic Role of Sarcopenia in Wilms Tumor: Does It Influence Surgical Outcomes and Survival?. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31828
Vancouver
Muñoz-Serrano AJ, Ramírez-Amoros C, Barrena Delfa S, Oterino C, Navarro G, Rubio Aparicio P, et al. The Prognostic Role of Sarcopenia in Wilms Tumor: Does It Influence Surgical Outcomes and Survival?. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31828
BibTeX
@article{MuozSerrano2025,
author = {Muñoz-Serrano, Antonio J and Ramírez-Amoros, Carla and Barrena Delfa, Saturnino and Oterino, César and Navarro, Gema and Rubio Aparicio, Pedro and Pérez-Martínez, Antonio and Martínez-Urrutia, María José and Martínez, Leopoldo},
title = {The Prognostic Role of Sarcopenia in Wilms Tumor: Does It Influence Surgical Outcomes and Survival?},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31828}
}
EUVIMED